Long acting GLP-1 receptor agonist (injectable)
Albiglutide 15 mg injection every 2 weeks
ALBI_SC_15MG_Q2W
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 30 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.70 (0.11 to 2.73) | 0.61 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.88 (0.78 to 4.26) | 0.62 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.56 (0.35 to 5.65) | 0.64 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.87 (0.24 to 2.60) | 0.72 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.19 (0.00 to 2.86) | 0.85 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.92 (0.05 to 15.88) | 0.46 |